CU23950B1 - Péptidos cíclicos con actividad antineoplásica y antiangiogénica - Google Patents

Péptidos cíclicos con actividad antineoplásica y antiangiogénica

Info

Publication number
CU23950B1
CU23950B1 CU2011000067A CU20110067A CU23950B1 CU 23950 B1 CU23950 B1 CU 23950B1 CU 2011000067 A CU2011000067 A CU 2011000067A CU 20110067 A CU20110067 A CU 20110067A CU 23950 B1 CU23950 B1 CU 23950B1
Authority
CU
Cuba
Prior art keywords
cyclic peptides
antineoplassic
antiangiogenic activity
systems
nanobiotechnology
Prior art date
Application number
CU2011000067A
Other languages
English (en)
Other versions
CU20110067A7 (es
Inventor
Pérez María Del Carmen Abrahantes
Santiago Glay Chinea
Díaz Eduardo Martínez
Pérez Hilda Elisa Garay
Acosta Osvaldo Reyes
Mola Ernesto López
Abad Cruz Matilde López
Blanco Sonia González
Original Assignee
Ct De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingeniería Genética Y Biotecnología filed Critical Ct De Ingeniería Genética Y Biotecnología
Priority to CU2011000067A priority Critical patent/CU23950B1/es
Priority to JP2014500249A priority patent/JP6032854B2/ja
Priority to RU2013146690/10A priority patent/RU2603286C2/ru
Priority to BR112013024265-5A priority patent/BR112013024265B1/pt
Priority to AU2012231427A priority patent/AU2012231427B2/en
Priority to PCT/CU2012/000002 priority patent/WO2012126441A2/es
Priority to CN201280021627.4A priority patent/CN103534265B/zh
Priority to ES12716190.9T priority patent/ES2644554T3/es
Priority to KR1020137027692A priority patent/KR101958964B1/ko
Priority to CA2830325A priority patent/CA2830325C/en
Priority to MX2013010813A priority patent/MX348677B/es
Priority to ARP120100930A priority patent/AR088727A1/es
Priority to EP12716190.9A priority patent/EP2690107B1/en
Priority to US14/005,855 priority patent/US9375459B2/en
Publication of CU20110067A7 publication Critical patent/CU20110067A7/es
Priority to ZA2013/07037A priority patent/ZA201307037B/en
Priority to CO13248567A priority patent/CO6801641A2/es
Publication of CU23950B1 publication Critical patent/CU23950B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a péptidos cíclicos con propiedades antitumorales y antiangiogénicas, así como a sus sales farmacéuticamente aceptables y a las composiciones farmacéuticas que los contienen. Estos péptidos cíclicos se emplean en la preparación de medicamentos para la terapéutica humana y/o veterinaria, y también pueden emplearse en el diagnóstico. Estos compuestos pueden ser usados para detectar, monitorear y/o controlar una variedad de desórdenes relacionados con la proliferación celular, tales como las enfermedades oncológicas y la angiogénesis no deseada. Además, pueden formar parte de sistemas de liberación controlada y en el campo de la nanobiotecnología, ya sea por su capacidad de autoensamblaje o como parte de otros sistemas.
CU2011000067A 2011-03-21 2011-03-21 Péptidos cíclicos con actividad antineoplásica y antiangiogénica CU23950B1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CU2011000067A CU23950B1 (es) 2011-03-21 2011-03-21 Péptidos cíclicos con actividad antineoplásica y antiangiogénica
ES12716190.9T ES2644554T3 (es) 2011-03-21 2012-03-21 Péptidos cíclicos con actividad antiangiogénica y antineoplásica
MX2013010813A MX348677B (es) 2011-03-21 2012-03-21 Peptidos ciclicos con actividad antineoplasica y antiangiogenica.
BR112013024265-5A BR112013024265B1 (pt) 2011-03-21 2012-03-21 peptídeos cíclicos, composição farmacêutica, composto para o diagnóstico de câncer, e, combinação farmacêutica
AU2012231427A AU2012231427B2 (en) 2011-03-21 2012-03-21 Cyclic peptides with an anti-neoplasic and anti-angiogenic activity
PCT/CU2012/000002 WO2012126441A2 (es) 2011-03-21 2012-03-21 Péptidos cíclicos con actividad antineoplásica y antiangiogénica.
CN201280021627.4A CN103534265B (zh) 2011-03-21 2012-03-21 具有抗肿瘤形成和抗血管生成活性的环肽
JP2014500249A JP6032854B2 (ja) 2011-03-21 2012-03-21 抗新生物及び抗血管新生活性を有する環状ペプチド
KR1020137027692A KR101958964B1 (ko) 2011-03-21 2012-03-21 항종양 및 항혈관생성 활성을 갖는 사이클릭 펩타이드
CA2830325A CA2830325C (en) 2011-03-21 2012-03-21 Cyclic peptides with an anti-neoplasic and anti-angiogenic activity
RU2013146690/10A RU2603286C2 (ru) 2011-03-21 2012-03-21 Циклические пептиды с антинеопластической и антиангионенной активностью
ARP120100930A AR088727A1 (es) 2011-03-21 2012-03-21 Peptidos ciclicos con actividad antineoplasica y antiangiogenica
EP12716190.9A EP2690107B1 (en) 2011-03-21 2012-03-21 Cyclic peptides with an anti-neoplasic and anti-angiogenic activity
US14/005,855 US9375459B2 (en) 2011-03-21 2012-03-21 Cyclic peptides with an anti-neoplasic and anti-angiogenic activity
ZA2013/07037A ZA201307037B (en) 2011-03-21 2013-09-18 Cyclic peptides with an anti-neoplastic and anti-angiogenic activity
CO13248567A CO6801641A2 (es) 2011-03-21 2013-10-21 Péptidos cíclicos con actividad con actividad antineoplásica y antiangiogénica

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2011000067A CU23950B1 (es) 2011-03-21 2011-03-21 Péptidos cíclicos con actividad antineoplásica y antiangiogénica

Publications (2)

Publication Number Publication Date
CU20110067A7 CU20110067A7 (es) 2012-10-15
CU23950B1 true CU23950B1 (es) 2013-10-29

Family

ID=46000593

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000067A CU23950B1 (es) 2011-03-21 2011-03-21 Péptidos cíclicos con actividad antineoplásica y antiangiogénica

Country Status (16)

Country Link
US (1) US9375459B2 (es)
EP (1) EP2690107B1 (es)
JP (1) JP6032854B2 (es)
KR (1) KR101958964B1 (es)
CN (1) CN103534265B (es)
AR (1) AR088727A1 (es)
AU (1) AU2012231427B2 (es)
BR (1) BR112013024265B1 (es)
CA (1) CA2830325C (es)
CO (1) CO6801641A2 (es)
CU (1) CU23950B1 (es)
ES (1) ES2644554T3 (es)
MX (1) MX348677B (es)
RU (1) RU2603286C2 (es)
WO (1) WO2012126441A2 (es)
ZA (1) ZA201307037B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201536814A (zh) * 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
US9908919B2 (en) * 2013-07-25 2018-03-06 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
PE20160991A1 (es) * 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
CA2945945C (en) 2014-04-15 2023-10-03 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
CN109503701B (zh) * 2018-07-20 2022-03-15 北京工业大学 一种环肽及其在制备抗肿瘤药物中的应用
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
CN111662363A (zh) * 2020-06-22 2020-09-15 上海大学 环肽类抗肿瘤活性化合物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539204A1 (en) 2002-08-30 2005-06-15 Biopharmacopae Design International Inc. Plant extracts for treatment of angiogenesis and metastasis
CU23475A1 (es) 2004-07-08 2009-12-17 Ct Ingenieria Genetica Biotech Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas
WO2007022557A1 (en) 2005-08-23 2007-03-01 Diatech Pty Ltd Mimotopes of epstein-barr virus (ebv) epitopes
BRPI0617186A2 (pt) * 2005-10-08 2011-07-19 Potentia Pharmaceuticals Inc uso de análogo de compstatina, implante ocular, micropartìcula ou nanopartìcula, composição, composto multivalente, ácido nucléico, vetor de expressão, célula hospedeira recombinante, proteìna de fusão e método de produção e teste
ITTO20060852A1 (it) * 2006-11-30 2008-06-01 Univ Degli Studi Torino Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche
CA2695960A1 (en) * 2007-08-08 2009-03-12 The Board Of Regents Of The University Of Texas System Vegfr-1/nrp-1 targeting peptides
CN102105487A (zh) * 2008-06-20 2011-06-22 得克萨斯大学体系董事会 靶向crkl的肽
US20100015058A1 (en) * 2008-06-25 2010-01-21 Stanford University Radiolabeled bbn-rgd heterodimers for cancer targeting

Also Published As

Publication number Publication date
JP6032854B2 (ja) 2016-11-30
CN103534265B (zh) 2016-06-08
WO2012126441A3 (es) 2012-11-22
JP2014513066A (ja) 2014-05-29
CA2830325A1 (en) 2012-09-27
ES2644554T3 (es) 2017-11-29
ZA201307037B (en) 2014-06-25
MX348677B (es) 2017-06-23
CO6801641A2 (es) 2013-11-29
AU2012231427A1 (en) 2013-10-03
CN103534265A (zh) 2014-01-22
EP2690107B1 (en) 2017-08-02
BR112013024265A2 (pt) 2016-12-27
BR112013024265B1 (pt) 2020-12-08
EP2690107A2 (en) 2014-01-29
RU2013146690A (ru) 2015-04-27
KR101958964B1 (ko) 2019-07-02
CU20110067A7 (es) 2012-10-15
US20140112976A1 (en) 2014-04-24
MX2013010813A (es) 2013-10-07
RU2603286C2 (ru) 2016-11-27
AR088727A1 (es) 2014-07-02
KR20140042796A (ko) 2014-04-07
AU2012231427B2 (en) 2016-08-04
US9375459B2 (en) 2016-06-28
CA2830325C (en) 2019-09-10
WO2012126441A2 (es) 2012-09-27

Similar Documents

Publication Publication Date Title
CU20110067A7 (es) Péptidos cíclicos con actividad antineoplásica y antiangiogénica
UY35142A (es) Derivados de triazolopirazinas como inhibidores de brd4
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CR20140513A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
NI201400108A (es) Compuestos de heterociclilo
MX2012012277A (es) Compuestos organicos.
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
DOP2015000170A (es) Compuestos químicos
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
UY35668A (es) Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen
CR20140516A (es) Compuestos de pirazol sustituidos como antagonistas de lpar
EA201600434A1 (ru) Применение производных бензимидазолпролина
PE20160183A1 (es) FORMULACION DE LIBERACION MODIFICADA DEL ACIDO (-)-(3aR,4S,7aR)-4-HIDROXI-4m-TOLILETINIL-OCTAHIDRO-INDOL-1-CARBOXILICO (AFQ056)
MY173564A (en) Cxcr7 receptor modulators
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales